← Back to Clinical Trials
Recruiting NCT07474337

NCT07474337 The Effect of Mindfulness-Based Breathing Exercises on Symptom Control

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07474337
Status Recruiting
Phase
Sponsor Firat University
Condition Breast Cancer
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2026-03-10
Primary Completion 2026-06-15

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Mindfulness-Based Breathing Exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2026-03-10 with a primary completion date of 2026-06-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled experimental study aims to evaluate the effect of mindfulness-based breathing exercises on symptom management and salivary cortisol levels in breast cancer patients receiving chemotherapy. The study population will consist of breast cancer patients undergoing chemotherapy treatment in the Oncology Department of Fırat University Hospital. A total of 72 patients who meet the inclusion criteria and volunteer to participate will be included in the study, with 36 patients in the experimental group and 36 in the control group. Data will be collected using the Personal Information Form and the Edmonton Symptom Assessment Scale. The findings of this study are expected to provide evidence regarding the effectiveness of mindfulness-based breathing exercises in improving symptom management and reducing stress levels in breast cancer patients receiving chemotherapy.

Eligibility Criteria

Inclusion Criteria: * Being over 18 years of age * Knowing their diagnosis * Receiving chemotherapy for the first time due to a breast cancer diagnosis * Having breast cancer stages I, II, or III (stage 4 patients were not included in the study as metastatic spread would increase symptoms and make communication with the patient difficult), * Not receiving treatment for another cancer, * Not having a physical disability that would prevent telephone interviews (hearing, speech), * Not having any psychiatric disorder that would impair comprehension and understanding, * Patients who have verbally and in writing consented to participate in the study will be included in the research. Exclusion Criteria: * Patients with communication problems • Patients with psychiatric problems

Frequently Asked Questions

Who can join the NCT07474337 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07474337 currently recruiting?

Yes, NCT07474337 is actively recruiting participants. Visit ClinicalTrials.gov or contact Firat University to inquire about joining.

Where is the NCT07474337 trial being conducted?

This trial is being conducted at Elâzığ, Turkey (Türkiye).

Who is sponsoring the NCT07474337 clinical trial?

NCT07474337 is sponsored by Firat University. The trial plans to enroll 72 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology